Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

biopharmadive.com image

News from biopharmadive.com

See all of biopharmadive.com news coverage in one place. Discover how biopharmadive.com’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 224 stories from biopharmadive.com over the past 3 months.

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Kennedy names 8 vaccine committee replacements, including COVID shot critic

US Politics · United States

Kennedy names 8 vaccine committee replacements, including COVID shot critic

60% Center coverage: 233 sources

U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week.See the Story

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

Europe · Germany

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

47% Center coverage: 28 sources

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.See the Story

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults

FDA · United States

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults

72% Center coverage: 18 sources

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

100% Center coverage: 2 sources

(MedPage Today) -- The FDA approved taletrectinib (Ibtrozi) -- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...Pharma · United States See the Story

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company - Novo Nordisk (NYSE:NVO)

57% Center coverage: 7 sources

Novo Nordisk A/S (NYSE:NVS) announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development in weight management. Amycretin is developed for subcutaneous and oral administration. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. Novo Nordisk p…Obesity · Denmark See the Story

AstraZeneca Forms an AI Deal in China; Third Harmonic Advances Liquidation Plans

67% Right coverage: 3 sources

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.Asia · China See the Story

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

100% Center coverage: 3 sources

Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year. The post Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer appeared first on MedCity News.See the Story

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

100% Center coverage: 5 sources

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support clinical development of lead program SB-007 in Stargardt diseaseFunding will also advance a broader pipeline…Startups See the Story

Pharma’s wins and losses in the budget bill

100% Center coverage: 2 sources

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.Pharma See the Story

Insmed Surges on Lung Drug Data; Recursion Cuts Staff

100% Center coverage: 2 sources

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several HIV studies.Wall Street · United States See the Story

National Resilience, a Well-Funded Manufacturing Startup, to Scale Back Operations

100% Center coverage: 3 sources

The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”Startups See the Story

Breaking News Topics Related to biopharmadive.com